Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca to present next wave of science in respiratory disease at ERS International Congress

65 abstracts to be presented from AstraZeneca's respiratory portfolio
and pipeline including Symbicort in mild to moderate asthma, and
Breztri and Fasenra in COPD

AstraZeneca will present new data on its portfolio of inhaled
combination and biologic therapies, and pipeline of emerging
medicines at the European Respiratory Society (ERS) International
Congress, which takes place from 28[ ]September to 2 October in
Madrid, Spain. The breadth and depth of science is reflected in the
65 abstracts accepted, including 17 oral presentations.

In inhaled combinations, a new analysis from the Phase III KRONOS
trial will be presented assessing the benefit of triple-combination
therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol
fumarate) on exacerbation rates over time in patients with moderate
to very severe chronic obstructive pulmonary disease (COPD).

In addition, data will be presented from PRACTICAL[1], an independent
trial investigating Symbicort Turbuhaler (budesonide/formoterol) used
as an anti-inflammatory reliever in mild to moderate asthma.
Following Novel START[2], PRACTICAL is the second trial designed to
reflect real-world practice comparing Symbicort Turbuhaler used as an
anti-inflammatory reliever therapy to current standard of care in
mild to moderate asthma.

In biologics, highlights will include a new analysis of the Phase III
GALATHEA and TERRANOVA trials for Fasenra (benralizumab), a potential
treatment in COPD, which identifies the clinical characteristics of
COPD patients who may benefit from Fasenra.

Tom Keith-Roach, Senior Vice President, Respiratory, said: "The
PRACTICAL and KRONOS data show that Symbicort Turbuhaler
anti-inflammatory reliever therapy and Breztri Aerosphere have the
potential to transform care and improve outcomes for patients. With
65 abstracts and 17 oral presentations, the breadth and depth of data
at the ERS International Congress reflect AstraZeneca's commitment to
respiratory medicine and represent the next wave of science in
respiratory disease."

AstraZeneca key abstracts at the ERS International Congress include:

Symbicort Turbuhaler

· Impact of COPD symptom-related attacks on quality of life and
exacerbations (Late-breaker Oral Presentation, #OA258, Sunday 29
September, 08:30-10:30, session 53/room 6F)

· SABA overuse and risk of mortality in a nationwide Swedish asthma
cohort (HERA) (Late-breaker Oral Presentation, #OA2105, Monday 30
September, 10:45-12:45, session 250/room 8A)

· Use of short-acting beta2 agonists (SABA) and exacerbations in a
nationwide Swedish asthma cohort (HERA) (Thematic Poster, #PA2554,
Monday 30[ ]September, 12:50-14:40, session 281/room TP-16)

· SABA and ICS use among mild asthma patients in UK primary care
(Thematic Poster, #PA2565, Monday 30[ ]September, 12:50-14:40,
session 281/room TP-16)

· Cost effectiveness of as-needed budesonide/formoterol vs low-dose
ICS maintenance therapy in mild asthma patients: A UK perspective
(Late-breaker Poster Discussion, #PA1964, Monday 30 September,
08:30-10:30, session 230/room 6B)

· Open-label trial of budesonide/formoterol reliever therapy in mild
asthma (Late-breaker Oral Presentation, #OA5332, Wednesday 2 October,
10:45-12:45, session 552/room 6F)

Breztri Aerosphere

· Effect of COPD exacerbations on early lung function decline under
maintenance therapy: blood eosinophil count as biomarker (Oral
Presentation, #OA 2154, Monday 30 September, 10:45-12:45, session
256/room N101 + 102)

· Analysis of exacerbation rates by time interval post-randomization
in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol
fumarate dihydrate metered dose inhaler (BGF MDI) (Thematic Poster,
#PA2481, Monday 30 September, 12:50-14:40, session 277/room TP-12)

· Pneumonia risk with budesonide-containing therapies in COPD:
pooled analysis of three Phase III studies (Poster Discussion,
#PA3375, Monday 30 September, 14:45-16:45, session 356/room 6D)


· Identification of patients with COPD who benefit from benralizumab
(Late-breaker Clinical Trials Session, #RCT446, Sunday 29 September,
10:45-12:45, session 76/room 9C)

· Baseline predictors of being exacerbation-free during 2 years of
benralizumab treatment (Oral Presentation, #OA5337, Wednesday 2
October, 10:45-12:45, session 552/room 6F)

Potential new medicines and breakthrough research

· Multiple ascending dose study of the inhaled IL-4Ra antagonist,
AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO
reduction and a promising clinical profile for the treatment of
asthma (Late-breaker Poster Discussion, #PA3709, Tuesday 1 October,
08:30-10:30, session 400, room RETIRO)

· Phase 1 evaluation of the inhaled IL-4Ra antagonist,
AZD1402/PRS-060, a potent and selective blocker of IL-4Ra (Oral
Presentation, #OA5336, Wednesday 2 October, 10:45-12:45, session
552/room 6F)

· First clinical results from AZD8154 (a selective PI3K??
inhibitor); Safety, tolerability and pharmacokinetics of AZD8154
after single ascending inhaled doses in healthy volunteers (Thematic
Poster, #PA4220, Tuesday 1 October, 12:50-14:40, session 445/room

Real world evidence

· Characteristics by physician-assigned severity of asthma, asthma +
COPD and COPD patients in the NOVELTY study (Poster Discussion,
#PA5029, Tuesday 1 October, 14:45-16:45, session 551/room 6D)

· Epidemiology of lung function in a global severe asthma population
(Poster Discussion, PA5023, Tuesday 1 October, 14:45-16:45, session
511/room 6D). ISAR is conducted by Optimum Patient Care Global
Limited, and co-funded by OPC Global and AstraZeneca

About AstraZeneca in respiratory diseases

Respiratory is one of AstraZeneca's three therapy areas, and our
medicines reached more than 18 million patients as maintenance
therapy in 2018. AstraZeneca's aim is to transform asthma and COPD
treatment through inhaled combinations at the core of care, biologics
for the unmet needs of specific patient populations, and scientific
advancements in disease modification.

The Company is building on a 40-year heritage in respiratory disease
and AstraZeneca's capability in inhalation technology spans
pressurised metered-dose inhalers and dry powder inhalers, as well as
the Aerosphere delivery technology. The company also has a growing
portfolio of respiratory biologics including Fasenra
(anti-eosinophil, anti-IL5 receptor alpha), now approved for severe,
eosinophilic asthma and in development for severe nasal polyposis and
other potential indications, and tezepelumab (anti-TSLP), which has
been granted Breakthrough Therapy Designation by the US Food and Drug
Administration in patients with severe asthma and is in Phase III
trials. AstraZeneca's research aims at addressing underlying disease
drivers by focusing on the lung epithelium, lung immunity, lung
regeneration and neuronal functions.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal and Metabolism
(CVRM), and Respiratory. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit (
and follow us on Twitter @AstraZeneca

Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677

Thomas Kudsk +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals (CV, metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (respiratory, renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Corporate access, retail investors +44 203 749 5824
US toll-free +1 866 381 72 77


1. Hardy J, Baggott C, Fingleton J, et al. Open-label trial of
budesonide/formoterol reliever therapy in mild asthma. Lancet. 2019;
published online August 23, 2019

2. Beasley RW, Holliday M, Reddel HK, et al. Controlled trial of
budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;
Epub ahead of print (DOI: 10.1056/NEJMoa1901963)


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.